Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in l.

Business Wire • Oct 22, 2026

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to.

Business Wire • Oct 14, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appr.

Business Wire • Oct 9, 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endoc.

Business Wire • Oct 8, 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling first-in-human dataset from the nPulse Cardiac Catheter System created significant investigator interest within the EP community across the United States," said Vive.

Business Wire • Oct 7, 2026

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Saraso.

Business Wire • Sep 15, 2026

Why Pulse Biosciences Stock Popped Today

An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in particular is ripe for disruption by the company.

The Motley Fool • Sep 9, 2026

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.

MarketBeat • Aug 16, 2026

Pulse Biosciences Q2 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.

MarketBeat • Aug 7, 2026

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026